The SINDAS trial (NCT02893332), a randomized, phase III study, aimed to address the benefit of LAT associated with targeted therapy in patients with EGFR-mutated synchronous OMD-NSCLC, with a maximum of five lesions. Here, EGFR is linked to non-small cell lung carcinoma.